Services - Altogen Labs

Xenograft model platforms:

Validated Xenograft Models — in-house validated CDX, PDX and syngeneic tumor models across all major indications.
Cell Line-Derived Xenograft (CDX) Models — fastest route to interpretable in vivo efficacy data.
Orthotopic Xenograft Models — tumors implanted at the anatomically matched organ site.
Metastasis and Disseminated Xenograft Models — intravenous, intracardiac and intrasplenic routes with imaging-based monitoring.
Treatment Resistance and Relapse Models — models derived under therapeutic pressure for next-line candidate testing.
Rat Xenograft Models — larger host supporting serial sampling and tumors that grow poorly in mice.
Xenograft Animal Service: Immunocompromised NOD/SCID Mice — standard subcutaneous efficacy study service.
Syngeneic Models — murine tumor lines in fully immunocompetent hosts.

PDX (patient-derived xenograft) services:

PDX Xenograft Models — patient tumor tissue engrafted without long-term culture.
PDX Models: Lung, Pancreatic, Prostate, Colorectal, Breast — established patient-derived models in five key indications.
Patient-Derived Orthotopic Xenograft (PDOX) Models — donor tissue implanted at the matched primary site.
Subrenal Capsule PDX Models (PDX-SRC) — highly vascularized site improving take rate for difficult tumors.
Humanized PDX Models (huPDX) — patient tumor and human immune compartment in the same host.
14 Weeks PDX and Chemotherapy Testing — fixed-timeline patient-derived xenograft efficacy package.

Humanized mouse models:

Humanized Mouse Models — human immune reconstitution for agents that do not engage mouse targets.
PBMC Humanized Mouse Models — rapid T-cell reconstitution for short-window studies.
CD34+ HSC Humanized Mouse Models — multi-lineage human immune system supporting longer study durations.
ATO-Supported CD34+ HSC Humanized BLT Models — artificial thymic organoid support for improved T-cell education.
iPSC Humanized Mouse Models — induced pluripotent stem cell-derived immune reconstitution.

Brain cancer xenograft models:

Breast cancer xenograft models:

Colon cancer xenograft models:

Gastric cancer xenograft models:

Kidney cancer xenograft models:

Liver cancer xenograft models:

Leukemia xenograft models:

Lung cancer xenograft models:

Lymphoma and myeloma xenograft models:

Melanoma xenograft models:

Ovarian cancer xenograft models:

Pancreatic cancer xenograft models:

Prostate cancer xenograft models:

Sarcoma xenograft models:

Other xenograft models (bladder, cervical, tongue, thyroid, endometrial, mesothelioma, germ cell):

Preclinical research services (biotechnology and pharmacology):

Pre-Clinical Research Services — pharmacology, exposure and biodistribution studies supporting drug development.
Biology Laboratory CRO Services — overview of efficacy and safety study capabilities.
In Vivo Pharmacology Services — efficacy and mechanism studies in disease-relevant animal models.
Pharmacokinetic/Pharmacodynamic (PK/PD) Studies — exposure-response relationships linking dose to target engagement.
ADME/DMPK Services — absorption, distribution, metabolism and excretion characterization.
Blood-Brain Barrier Model Development Services — CNS penetration assessment for neurological candidates.
In Vivo Imaging and Biodistribution Services — bioluminescent and fluorescent tracking of tumors and test articles.
IND-Enabling Preclinical Studies — integrated efficacy, PK and safety packages for regulatory submission.
Genetically Engineered Mouse Model (GEMM) Development Services — custom transgenic and knockout model generation.
GEMM-Derived Allograft (GDA) Model Development Services — transplantable tumors from genetically engineered donors.
Teratoma Formation and Analysis Service — in vivo pluripotency assay for iPSC and ESC lines.

Immuno-oncology services:

Immuno-Oncology Services — model selection and study design for immunotherapy programs.
Immuno-Oncology Models — platform selection for immune-mediated mechanisms.
CAR-T Cell Therapy Preclinical Models — efficacy and persistence testing for CAR-T products.
CAR-NK Cell Therapy Preclinical Models — engineered natural killer cell efficacy in humanized hosts.
NK Cell Therapy Preclinical Models — unmodified and expanded NK cell product testing.
Gamma Delta (γδ) T-Cell Therapy Preclinical Models — MHC-independent T-cell therapy evaluation.
Bispecific Antibody Preclinical Models — T-cell engager efficacy with human effector cells present.
Immune Checkpoint Inhibitor Preclinical Models — anti-PD-1, anti-PD-L1 and anti-CTLA-4 benchmark and combination studies.

Patient-derived models:

Patient-Derived Models — tumor tissue, cells and organoids established directly from patient material.
Organoid-Derived Xenograft (ODX) Models — ex vivo expansion and screening before engraftment.
Patient-Derived Tumor Organoids (PDTO) — three-dimensional tumor cultures for ex vivo drug response screening.
Patient-Derived Cells (PDC) — low-passage primary tumor cultures retaining donor genotype.
3D Tumor Models — spheroid and matrix-embedded culture systems for compound screening.
Personalized Oncology — patient-specific model panels for treatment selection and co-clinical studies.

Safety toxicology services:

Safety Toxicology Services — GLP-compliant toxicology supporting IND and regulatory submissions.
Dose Range-Finding and Maximum Tolerated Dose (MTD) Studies — dose selection in mouse and rat ahead of definitive studies.
Safety Pharmacology Services — cardiovascular, respiratory and CNS core battery assessments.
Immunotoxicity Testing Services — immune function and immunophenotyping endpoints in repeat-dose studies.
Biocompatibility Testing Services — ISO 10993-aligned testing for medical devices and materials.
In Vivo Toxicology Service (Mouse, Rat) — acute and repeat-dose in vivo safety assessment.
Acute Toxicology Test OECD 425 — up-and-down procedure establishing LD50 with confidence intervals.
Acute Dermal Toxicity OECD 402 — single-dose dermal exposure with 14-day observation.
Acute Inhalation Toxicity OECD 403 — controlled aerosol exposure for inhaled test articles.
Acute Dermal Irritation OECD 404 — four-hour semi-occlusive exposure with GHS classification.
Oral Toxicity OECD 408 — 90-day subchronic toxicity with clinical pathology and histopathology.
Toxicokinetics OECD 417 — systemic exposure characterization integrated with toxicology studies.
Chronic Toxicity OECD 452 — twelve-month repeat-dose toxicity in rodent species.
Carcinogenicity OECD 453 — combined chronic toxicity and carcinogenicity with interim sacrifice satellites.

In vitro oncology services:

In Vitro Oncology Services — potency, selectivity and mechanism established in culture before in vivo work.
Cell Proliferation and Viability Assays — dose-response viability testing across cancer cell line panels.
Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines — IC50 determination with curve fits and confidence intervals.
Combination Drug Studies and Synergy Testing — matrix dosing with Bliss and Loewe synergy analysis.
Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen — quantified apoptosis induction with time-course readouts.
NCI-60 Human Tumor Cell Line Screen Service — broad cancer cell line panel screening for mechanism inference.
ELISA and Cell-Based Assay Development (Cell Cycle, Viability) — custom assay development for biomarkers and cytokines.

Molecular biology services:

Molecular Biology Services — sample analysis supporting in-life efficacy and safety studies.
Gene Expression Analysis (RT-PCR/qPCR) — quantitative transcript measurement in cells and tissues.
Protein Expression Analysis Services: Wes and Western — automated capillary and traditional Western immunoassay.
Immunohistochemistry (IHC) Services — marker localization and scoring in tumor and normal tissue.
Flow Cytometry Services — immunophenotyping of blood, spleen and tumor-infiltrating cells.
Cytokine Analysis Services — multiplex cytokine quantification in serum and tissue lysate.
Clinical Pathology Services: Blood Chemistry and Hematology Analysis — organ function and hematology panels for safety endpoints.
Necropsy and Tissue Collection Services — gross pathology with protocol-defined tissue preservation.
Histopathology Services — sectioning, staining and pathologist evaluation of study tissues.
RNA, DNA, and Protein Isolation Services — nucleic acid and protein extraction from cells and tissues.
PCR Cloning: DNA Vector Construction (shRNA) — sequence-verified vector construction and endotoxin-free preparation.

Development of stable cell lines services:

Generation of Stable Cell Lines — custom stable mammalian cell line development and validation.
Generation of Stable Cell Line in 28 Days — validated clonal lines delivered with expression data and frozen stocks.
Protein Overexpression: Mammalian Stable Cell Line Development — high-expressing clones for recombinant protein production.
Stable RNAi Cell Line Development: shRNA Gene Knockdown — constitutive knockdown lines with validated silencing.
Reporter Stable Cell Line Generation — luciferase and fluorescent reporter lines for imaging and screening.
CRISPR/Cas9 Gene Editing Services — knockout, knock-in and edited line generation with validation.

Formulation and encapsulation services:

Formulation and Encapsulation Services — delivery vehicles for small molecules, proteins and nucleic acids.
Nanoparticle Encapsulation and Formulation Services — particle formulation with size, PDI and encapsulation efficiency data.
Liposome Encapsulation Services: siRNA, miRNA, DNA, Proteins — liposomal formulation for in vivo delivery of diverse cargo.
siRNA Liposome Encapsulation Service — nuclease protection and tissue targeting for siRNA in vivo.

RNA interference (gene silencing) services:

RNA Interference (RNAi) Services — complete siRNA and shRNA gene silencing services, in vitro and in vivo.
In Vivo siRNA Delivery and Tissue Targeting (In Vivo RNAi) — systemic and local delivery with quantified tissue knockdown.
Therapeutic RNAi Development: Targeted siRNA, qPCR Assays — siRNA candidate development from design to in vivo knockdown.
Transient (siRNA) and Stable (shRNA) Transfection Services — optimized transfection across cell lines and primary cultures.
Stable RNAi Cell Line Generation: Stable Gene Knockdown — selected clones with durable target silencing.
Generation of Tet-inducible RNAi Gene Knockdown Cell Lines — doxycycline-controlled, reversible gene knockdown.
Quantitation sh/siRNA-induced Knockdown by qRT-PCR and WB — knockdown confirmed at transcript and protein level.
siRNA Transfection and RNAi Cell-based Library Screening — arrayed and pooled screening with transfection controls.
Genome-wide siRNA and microRNA High-throughput Screens — whole-genome and targeted library screens with hit calling.
RNAi Screen Pathway Analysis: siRNA and microRNA — pathway-level interpretation of screening results.
RNAi Development and CRO Services — end-to-end RNAi program support from target to in vivo study.
RNAi Consulting: Technology Development and Evaluation — target assessment and delivery strategy review.

Cryopreservation and cell banking services:

Cell Banking Services — cell bank generation, storage and release testing.
Cryopreservation and Cell Banking Service (GLP-compliant) — controlled-rate freezing with post-thaw viability validation.
Cell Banking Service: Master Cell Bank (MCB, WCB) Generation — two-tier banking with identity, sterility and mycoplasma testing.